Interleukin-1, neuroinflammation, and Alzheimer’s disease

Interleukin-1 (IL-1)-1) is a pluripotent immunomodulatory cytokine that has an initiating role in cellular and humoral immunity in the periphery. Il-1 is overexpressed in Alzheimer brain, and this overexpression is directly related to plaque formation and progression, nonsensical growth of dystrophic neurites, and neuronal overexpression of acetylcholinesterase. IL-1 has a number of actions relevant to Alzheimer's disease, including excessive expression of neuronal Abeta precursor protein and other plaque-associated proteins, and induction of astrocyte activation and astrocytic overexpression of S100B. These latter events may be related to the overgrowth of dystrophic neurites in neuritic plaques, a necessary event for conversion of diffuse Abeta deposits into the neuritic amyloid plaques diagnostic of Alzheimer's disease. Four new genetic studies underscore the relevance of IL-1 to Alzheimer pathogenesis, showing that homozygosity of a specific polymorphism in the IL-1A gene at least triples Alzheimer risk, especially for an earlier age of onset and in combination with homozygosity for another polymorphism in the IL-1B gene.

[1]  R. Mrak,et al.  Progressive Neuronal Injury Associated with Amyloid Plaque Formation in Alzheimer Disease , 1998, Journal of neuropathology and experimental neurology.

[2]  N. Rothwell,et al.  Potential mechanisms of interleukin-1 involvement in cerebral ischaemia , 1999, Journal of Neuroimmunology.

[3]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[4]  M. Folstein,et al.  Nonsteroidal anti-inflammatory drugs in Alzheimer's disease , 1995, Neurology.

[5]  S. Barger,et al.  Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E , 1997, Nature.

[6]  M. McInnis,et al.  Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies , 2000, Experimental Gerontology.

[7]  W. Oertel,et al.  Association of an interleukin 1α polymorphism with Alzheimer’s disease , 2000, Neurology.

[8]  J. Halaas,et al.  Leptin and the regulation of body weight in mammals , 1998, Nature.

[9]  P. Greengard,et al.  Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Marshak S100 beta as a neurotrophic factor. , 1990, Progress in brain research.

[11]  J. Krueger,et al.  Sleep: A Physiologic Role for IL‐1β and TNF‐α a , 1998, Annals of the New York Academy of Sciences.

[12]  A. Prochiantz,et al.  Brain macrophages synthesize interleukin‐1 and interleukin‐1 mRNAs in vitro , 1988, Journal of neuroscience research.

[13]  S. Barger,et al.  S100 beta stimulates calcium fluxes in glial and neuronal cells. , 1992, The Journal of biological chemistry.

[14]  W. Griffin,et al.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Mrak,et al.  Enlarged and phagocytic, but not primed, interleukin-1α-immunoreactive microglia increase with age in normal human brain , 1998, Acta Neuropathologica.

[16]  T. Iwatsubo,et al.  Association of A beta 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[17]  W. Griffin,et al.  Distribution of interleukin‐1‐immunoreactive microglia in cerebral cortical layers: implications for neuritic plaque formation in Alzheimer’s disease , 1998, Neuropathology and applied neurobiology.

[18]  Association of early‐onset Alzheimer's disease with an interleukin‐1α gene polymorphism , 2000, Annals of neurology.

[19]  R. Mrak,et al.  Glial Cytokines as Neuropathogenic Factors in HIV Infection: Pathogenic Similarities to Alzheimer's Disease , 1994, Journal of neuropathology and experimental neurology.

[20]  Y. Kiso,et al.  Interleukin-1 beta inhibits long-term potentiation in the CA3 region of mouse hippocampal slices. , 1990, European journal of pharmacology.

[21]  R. Płoski,et al.  A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1α polymorphism , 1995 .

[22]  L. V. Van Eldik,et al.  S100β Stimulates Inducible Nitric Oxide Synthase Activity and mRNA Levels in Rat Cortical Astrocytes (*) , 1996, The Journal of Biological Chemistry.

[23]  W. Griffin,et al.  Glial‐Neuronal Interactions in Alzheimer's Disease: The Potential Role of a ‘Cytokine Cycle’ in Disease Progression , 1998, Brain pathology.

[24]  R. Mrak,et al.  Glial Cytokines in Neurodegenerative Conditions , 2000 .

[25]  R. Dantzer,et al.  Interleukin-1 in the Brain , 1992 .

[26]  G. Forloni,et al.  Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. , 1992, Brain research. Molecular brain research.

[27]  J. Bockaert,et al.  “Inflammatory” Cytokines , 2000, Journal of neurochemistry.

[28]  J. Reul,et al.  Research and perspectives in neurosciences , 2000 .

[29]  Detlef Balschun,et al.  A neuromodulatory role of interleukin-1β in the hippocampus , 1998 .

[30]  I. J. McKay,et al.  Polymorphisms in the IL-1A Gene are Correlated with Levels of Interleukin-1α Protein in Gingival Crevicular Fluid of Teeth with Severe Periodontal Disease , 2000, Journal of dental research.

[31]  H J Koch,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[32]  D. Graham,et al.  Microglial interleukin-lα expression in human head injury: Correlations with neuronal and neuritic β-amyloid precursor protein expression , 1994, Neuroscience Letters.

[33]  W. Griffin,et al.  Microglial inter leukin‐1α expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution , 1995, Neuropathology and applied neurobiology.

[34]  Saumya Das,et al.  Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1 , 1995, Neuron.

[35]  V. Martinelli,et al.  Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients , 1999, Neurology.

[36]  H. W. Harris,et al.  Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Association of interleukin‐1 gene polymorphisms with Alzheimer's disease , 2000, Annals of neurology.

[38]  W. McDonald,et al.  Inverse association of anti‐inflammatory treatments and Alzheimer's disease , 1994, Neurology.

[39]  K. Davis,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[40]  G. Rebeck Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease , 2000, Neuroscience Letters.

[41]  A. Hofman,et al.  Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? , 1995, Neurology.

[42]  S. Hauser,et al.  Cytokine accumulations in CSF of multiple sclerosis patients , 1990, Neurology.

[43]  D W Dickson,et al.  Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. , 1993, Journal of immunology.

[44]  Alexey G. Murzin,et al.  β-Trefoil fold: Patterns of structure and sequence in the Kunitz inhibitors interleukins-1β and 1α and fibroblast growth factors , 1992 .

[45]  H. Wiśniewski,et al.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome , 1985, Annals of neurology.

[46]  F. Pociot,et al.  A Taql polymorphism in the human interleukin‐1β (IL‐1β) gene correlates with IL‐1β secretion in vitro , 1992 .

[47]  M. Pericak-Vance,et al.  Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs , 1995, Neurobiology of Aging.

[48]  S. Barger,et al.  Neuronal–Glial Interactions Mediated by Interleukin-1 Enhance Neuronal Acetylcholinesterase Activity and mRNA Expression , 2000, The Journal of Neuroscience.

[49]  G. Jackson,et al.  The hippocampal sclerosis whodunit: Enter the genes , 2000, Annals of neurology.

[50]  G. Annoni,et al.  Gene polymorphism affecting α1‐antichymotrypsin and interleukin‐1 plasma levels increases Alzheimer's disease risk , 2000, Annals of neurology.

[51]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[52]  M. Esiri,et al.  Prevalence of Alzheimer plaques in AIDS , 1998, Journal of neurology, neurosurgery, and psychiatry.

[53]  R. Mrak,et al.  Glial cytokines in Alzheimer's disease: review and pathogenic implications. , 1995, Human pathology.

[54]  K. Kanemoto,et al.  Interleukin (IL)‐1β, IL‐1α, and IL‐1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy , 2000 .

[55]  M. Hurme,et al.  Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. , 1998, Annals of medicine.

[56]  D Emilie,et al.  In vitro production of IL-6, IL-1 beta, and tumor necrosis factor-alpha by human embryonic microglial and neural cells. , 1993, Journal of immunology.

[57]  A. Heyman,et al.  Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. , 1991 .

[58]  R. Mrak,et al.  Interleukin‐1 Expression in Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evalution , 1995, Journal of neuropathology and experimental neurology.

[59]  R. Skinner,et al.  In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis , 1996, Neurobiology of Aging.

[60]  N. Rothwell,et al.  Interleukin 1 in the brain: biology, pathology and therapeutic target , 2000, Trends in Neurosciences.

[61]  R. Mrak,et al.  Increased Neuronal β‐Amyloid Precursor Protein Expression in Human Temporal Lobe Epilepsy: Association with Interleukin‐1α Immunoreactivity , 1994 .

[62]  K. Kornman,et al.  Genetic variations in cytokine expression: a risk factor for severity of adult periodontitis. , 1998, Annals of periodontology.

[63]  I. Mizuta,et al.  Influence of interleukin-1β gene polymorphisms on age-at-onset of sporadic Parkinson's disease , 2000, Neuroscience Letters.

[64]  D. Munoz,et al.  Role of microglia in senile plaque formation , 1995, Neurobiology of Aging.

[65]  L. Rosenwasser,et al.  Biologic activities of IL-1 and its role in human disease. , 1998, The Journal of allergy and clinical immunology.

[66]  S. Barger,et al.  S100β Induction of the Proinflammatory Cytokine Interleukin‐6 in Neurons , 2000, Journal of neurochemistry.

[67]  A. Heyman Head trauma as a risk factor for Alzheimer's disease , 1994, Journal of the Neurological Sciences.

[68]  W. Griffin,et al.  The role of chronic self-propagating glial responses in neurodegeneration: implications for long-lived survivors of human immunodeficiency virus. , 1997, Journal of neurovirology.

[69]  A. C. Webb,et al.  Interleukin-1: a gene expression system regulated at multiple levels. , 1994, European cytokine network.